EMERYVILLE, Calif.--(BUSINESS WIRE)--Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T-cell therapies to treat cancer, today announced the advancement of its ARYA-3 clinical trial to Phase II (NCT04864054). This milestone represents one of the first engineered T-cell programs targeting solid tumors to reach Phase II..

加利福尼亚州埃默里维尔（商业新闻短讯）--Eureka Therapeutics，Inc.，一家开发新型T细胞疗法治疗癌症的临床阶段生物技术公司，今天宣布其ARYA-3临床试验进入II期（NCT04864054）。这一里程碑代表了针对实体瘤达到II期的首批工程化T细胞计划之一。。

The ARYA-3 trial is evaluating Eureka’s investigational ARTEMIS® ECT204 T-cell therapy in adult patients with GPC3-positive advanced hepatocellular carcinoma (HCC), the predominant type of liver cancer. Glypican 3 (GPC3) is a promising target for HCC therapies and is found in more than 70% of HCC cells.

ARYA-3试验正在评估Eureka的ARTEMIS®ECT204 T细胞治疗成人GPC3阳性晚期肝细胞癌（HCC）（肝癌的主要类型）患者的研究。磷脂酰肌醇蛋白聚糖3（GPC3）是HCC治疗的有希望的靶标，并且在超过70%的HCC细胞中发现。

The GPC3 protein is also expressed in other solid tumors, including ovarian and lung cancer..

GPC3蛋白也在其他实体瘤中表达，包括卵巢癌和肺癌。。

The ARYA-3 trial has successfully completed Phase I and is now enrolling patients in Phase II. During this phase, the treatment’s efficacy and safety are evaluated in a larger patient population, offering crucial insights into its potential therapeutic benefits.

ARYA-3试验已成功完成第一阶段，目前正在招募第二阶段的患者。在此阶段，在更大的患者群体中评估治疗的有效性和安全性，为其潜在的治疗益处提供重要的见解。

“We are excited by the favorable safety profile and promising early efficacy signals in Phase I of our ARYA-3 study. Moving to Phase II marks a significant milestone in our mission to advance cutting-edge therapies for cancer treatment,” said Dr. Cheng Liu, President and CEO of Eureka Therapeutics. “We remain committed to building a pipeline of next-generation T-cell therapy for solid tumors.”.

Eureka Therapeutics总裁兼首席执行官Cheng Liu博士表示：“我们对ARYA-3研究第一阶段良好的安全性和有希望的早期疗效信号感到兴奋。进入第二阶段标志着我们推进癌症治疗前沿疗法使命的一个重要里程碑。”。“我们仍然致力于为实体瘤建立下一代T细胞疗法的管道。”。

ARYA-3 is an Open-Label, Dose Escalation, Multi-Center Phase I/II Clinical Trial of ECT204 T-Cell Therapy. In this study, a patient’s T cells are collected and genetically modified to express Eureka’s proprietary anti-GPC3 ARTEMIS T cell receptors (AbTCR). These modified T cells are then reintroduced into the patient to specifically seek out and destroy GPC3-expressing cancer cells.

ARYA-3是ECT204 T细胞疗法的开放标签，剂量递增，多中心I/II期临床试验。在这项研究中，收集患者的T细胞并进行基因修饰以表达Eureka专有的抗GPC3 ARTEMIS T细胞受体（AbTCR）。然后将这些修饰的T细胞重新引入患者体内，以特异性寻找并破坏表达GPC3的癌细胞。

Eureka has previously demonstrated that its proprietary ARTEMIS T-cell receptor platform has several advantages over conventional chimeric antigen receptors (CARs), including better tumor infiltration, safety, and T cell persistence. The clinical trial is actively enrolling patients at both City of Hope and Kansas University Medical Center..

Eureka先前已经证明，其专有的ARTEMIS T细胞受体平台比传统的嵌合抗原受体（CAR）具有多个优势，包括更好的肿瘤浸润，安全性和T细胞持久性。该临床试验正在霍普城和堪萨斯大学医学中心积极招募患者。。

Patients, caregivers and health care professionals interested in Eureka’s clinical trials and technology can find more information by visiting eurekaconnectme.com.

对Eureka临床试验和技术感兴趣的患者，护理人员和医疗保健专业人员可以通过访问eurekaconnectme.com找到更多信息。

ABOUT EUREKA THERAPEUTICS, INC.

关于EUREKA THERAPEUTICS，INC。

Eureka Therapeutics, Inc. is a privately held clinical-stage biotechnology company focused on developing novel T-cell therapies to treat cancers. Its core technology centers around its proprietary ARTEMIS® cell receptor platform and E-ALPHA® antibody discovery platform for the discovery and development of potentially safer and more effective T-cell therapies for the treatment of solid tumors and hematologic malignancies.

Eureka Therapeutics，Inc.是一家私营临床阶段生物技术公司，专注于开发新型T细胞疗法来治疗癌症。其核心技术围绕其专有的ARTEMIS®细胞受体平台和E-ALPHA®抗体发现平台，用于发现和开发潜在更安全和更有效的T细胞疗法，用于治疗实体瘤和血液系统恶性肿瘤。

The company currently has two clinical programs, ET140203 (ARYA-1 for adults and ARYA-2 for pediatrics) and ECT204 (ARYA-3), in Phase I/II US trials in patients with advanced liver cancer..

该公司目前在美国晚期肝癌患者的I/II期临床试验中有两个临床项目ET140203（成人为ARYA-1，儿科为ARYA-2）和ECT204（ARYA-3）。。

Eureka Therapeutics, Inc. is headquartered in the San Francisco Bay Area. For more information on Eureka, please visit www.eurekatherapeutics.com. ARTEMIS and E-ALPHA are registered trademarks owned by Eureka.

尤里卡治疗公司总部位于旧金山湾区。有关Eureka的更多信息，请访问www.eurekatherapeutics.com。ARTEMIS和E-ALPHA是Eureka拥有的注册商标。